Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis
Autor: | Till Plönes, Clemens Aigner, Christian Roesel, Stefan Welter, Gerhard Weinreich, Monika Serke, Karl-Otto Kambartel, Yazan Alnajdawi, Mohammed Ibrahim, Thomas Krbek |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Lung business.industry Lymphovascular invasion Large cell Medizin 030105 genetics & heredity 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure Internal medicine Tumor stage medicine Lymphatic vessel Retrospective analysis Original Article Large-cell neuroendocrine carcinoma business 030217 neurology & neurosurgery Blood vessel |
Popis: | Background: Large cell neuroendocrine carcinomas (LCNEC) are rare pulmonary malignancies. Reported survival rates are heterogeneous and the optimal therapeutic strategy is still debated. The prognosis of LCNEC is generally inferior compared to other non-small lung cancers. In early stages, surgery is recommended but might not be sufficient alone. Methods: We retrospectively analyzed all consecutive LCNEC patients operated at three institutions with curative intent between May 2005 and January 2017. Data retrieved from individual clinical databases were analyzed with the aim to identify prognostic parameters. Results: A total of 251 patients with LCNEC underwent curative intent surgery during the observation period. The median age was 64 years, 156 patients (62.2%) were male and 88.4% were smokers. The pathologic AJCC stage was I in 136 patients, II in 77, III in 33, and IV in 5 patients. Median followup was 26 months. Lymphatic vessel invasion (P=0.031) was identified as significant prognostic factor by multivariable analysis. There was a trend towards decreased survival in patients with blood vessel invasion (P=0.067). Even in earlier tumor stages, adjuvant chemotherapy had a positive effect on survival. The overall 1-, 3- and 5-year survival rates were 79.2%, 48.6% and 38.8% respectively. Conclusions: Lymphatic invasion (L1) is an independent prognostic factor. Surgery in LCNEC is beneficial in early tumor stages and platinum-based adjuvant chemotherapy may help in achieving better long-term outcomes resulting in most obvious survival differences in stage Ib. CA extern |
Databáze: | OpenAIRE |
Externí odkaz: |